CTRI/2010/091/000245已完成3 期
Comparative Evaluation of Efficacy and Safety of Primaquine SR Tablets Vs Primaquine Conventional Tablets in the Prevention of Relapse of Plasmodium Vivax Malaria.
试验速览
- 阶段
- 3 期
- 状态
- 已完成
- 入组人数
- 360
研究概览
简要总结
暂无简介。
研究设计
- 研究类型
- Interventional
入排标准
入选标准
- •1.Male and female patients aged 18 -65 years.2.Patients with confirmed cases of P. vivax malaria (asexual forms) by microscopy on a thin and thick blood smear with parasite count of >/=1,000/µL of blood.3.Patients with axillary temperature >/= 37.5 °C and with clinical signs and symptoms of malaria.4. Patients giving written informed consent to participate in this study.5.patients willing to undergo folloe-up for 2-6 months.
排除标准
- •1. Patients with Mixed malarial infection.
- •2.Patients with body weight 40 kg.
- •3.Patients with severe or complicated malaria.
- •4.Patients with glucose 6-phosphate dehydrogenase deficiency.
- •5.Patients with a history of dark urine or significant hemoglobinuria related to Primaquine treatment during the course of a pervious episode of malaria.
- •6.Patient with known history of methomoglobinemia.
- •7.Patients taking cardioactive drug or potentially hemolytic drugs.
- •8.Patients with concomitant illness (cardiac, hepatic or renal diseases-blood urea nitrogen (BUN) 20mg/dl or blood urea 40mg/dl, hepatic SGPT or SGOT 2.5 x ULN, serum bilirubin 2mg/dl and serum creatinine 1.5mg/dl)).
- •9. Patients previously treated with any other antimalarial therapy except chloroquine.
- •10.Patients showing any significant abnormality (clinical or laboratory) on pre-trial screening in the opinion of the investigator.
- •11. Patients with protracted vomiting and oliguria.
- •12.Patients with systolic BP 160 mm Hg and/or diastolic BP 110 mm Hg.
- •13.Patients with acute exacerbations of systemic diseases, having a tendency to granulocytopenia e.g. rheumatoid arthritis and lupus erythematosus.
- •14.Patients with underlying condition compromising bone marrow function or on medication which might compromise the bone marrow.
- •15.Patients with history of hypersensitivity to chloroquine, primaquine or aminoquinoline derivatives, or other similar drugs.
- •16. Patient having any concomitant medication which may interact with study drugs.
- •17.Patients on another investigational drug.
- •18. Patients unable to tolerate oral medication and known history of alcoholism.
- •19.Pregnant or lactating women.
- •20. Women of child bearing potential.
- •21.Patient with methomoglobinemia.
研究者
相似试验
已完成
不适用
To study and compare the injectable route with nasal route of drug delivery in reducing the heart rate and blood pressure during intubation(When a tube is passed through your mouth before surgery when you are unconscious).CTRI/2021/06/034309Arindam Chatterjee50
已完成
4 期
Self-administered fentanyl for birthing women.ChildbirthReproductive Health and Childbirth - Childbirth and postnatal careACTRN12609000006246Western Health50
已完成
不适用
The comparative study of the efficacy and safety of Simeprevir sodium at investigational stage and after marketing authorizatioChronic hepatitis CJPRN-UMIN000045086Shimane University98
已完成
3 期
Comparative study of the efficacy and safety of intrathecal hyperbaric ropivacaine with hyperbaric bupivacaine in patients undergoing caesarean section under spinal anaesthesiaCTRI/2023/06/054563Pt B D Sharma University of Health Sciences PGIMS Rohtak Haryana90
尚未招募
2 期
Comparison of the effect of Tulsi and Chlorhexidine mouth rinse on gum disease in controlled sugar patients aged 45-55 years in Davangere city.CTRI/2019/01/016960il